ArticleFrontiers in psychiatry2025
The value of repetitive transcranial magnetic stimulation combined with amisulpride enhancement olanzapine therapy for resistant treatment-refractory schizophrenia.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Repetitive transcranial magnetic stimulation (rTMS) is a widely used enhancement therapy for schizophrenia, but there are few controlled studies on the combination of rTMS and amisulpride enhancement therapy. The aim of this study is to explore the value of rTMS combined with amisulpride enhanced olanzapine therapy for resistant treatment-refractory schizophrenia (TRS) patients. Methods: We conducted a retrospective analysis based on records of TRS patients who received amisulpride enhanced olanzapine treatment at the Third People's Hospital of Yongkang City from December 2022 to September 2023. Patients are divided into rTMS group and Non-rTMS group based on whether they receive combined rTMS treatment. We examined the patient's Positive and Negative Symptom Rating Scale (PANSS) scores, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores, World Health Organization Quality of Life Questionnaire (WHOQOL-BREF), and incidence of adverse events. Results: After treatment, the scores of PANSS in both groups significantly decreased, and the rTMS group was lower than the Non-rTMS group (P<0.05); The scores of RBANS and WHOQOL-BREF in both groups significantly increased (P<0.05); Except for the attention sub item, all other sub scores in the rTMS group were higher than those in the Non-rTMS group (P<0.05); There was no significant difference in the total number of adverse events between the two groups (P>0.05). Conclusions: The combination of rTMS and amisulpride to enhance olanzapine treatment for TRS may offer potential benefits in symptom management, cognitive function, and quality of life. Core tip: rTMS is a widely used treatment method for schizophrenia. This study found that rTMS combined with amisulpride enhanced olanzapine treatment for TRS can significantly improve patients' symptoms, cognitive function, and quality of life, with tolerability and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.